These ACPA fine specificities have previously been reported as among the most prevalent in RA, typically at higher frequencies ranging from 60% to 80% in anti-CCP–positive RA patients and 3% to 9% in anti-CCP–negative RA patients [44]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.